Patents by Inventor Masanori Hatsuda
Masanori Hatsuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190048034Abstract: There is provided an efficient and excellent preparation method of an ?-halo-tetraacyl-glucose which is suitable for industrial preparation, which comprises reacting D-glucose or lower alkyl D-glucoside with a reactive derivative of a carboxylic acid and a metal halide to prepare the ?-halo-tetraacyl-glucose represented by the formula (III): wherein R represents an optionally substituted lower alkyl group or an optionally substituted aryl group, and X represents a halogen atom, in one step, and the resulting ?-halo-tetraacyl-glucose (III) can be converted into a compound of the formula (I) or a salt thereof by subjecting to a conventional method.Type: ApplicationFiled: October 19, 2018Publication date: February 14, 2019Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Keita UEDA, Masanori HATSUDA, Isao HYODO, Kouichi TANIMOTO
-
Publication number: 20160002276Abstract: There is provided an efficient and excellent preparation method of an ?-halo-tetraacyl-glucose which is suitable for industrial preparation, which comprises reacting D-glucose or lower alkyl D-glucoside with a reactive derivative of a carboxylic acid and a metal halide to prepare the ?-halo-tetraacyl-glucose represented by the formula (III): wherein R represents an optionally substituted lower alkyl group or an optionally substituted aryl group, and X represents a halogen atom, in one step, and the resulting ?-halo-tetraacyl-glucose (III) can be converted into a compound of the formula (I) or a salt thereof by subjecting to a conventional method.Type: ApplicationFiled: February 25, 2014Publication date: January 7, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Keita UEDA, Masanori HATSUDA, Isao HYODO, Kouichi TANIMOTO
-
Patent number: 9181217Abstract: The present invention provides an industrially advantageous method for producing an optically active naphthalene compound useful as a therapeutic agent for dermatitis or the like. Specifically, the present invention provides a method for producing an optically active naphthalene compound [I], which comprises: a step of reacting a compound [a-1] and a compound [b-1] with each other in the presence of a base and a catalyst that is composed of a Pd compound and a tertiary phosphine ligand (step a); a step of asymmetrically hydrogenating a compound [c-1] in the presence of a hydrogen donor and a complex that is prepared from a ruthenium compound and a chiral ligand, or alternatively in the presence of an optically active oxazaborolidine compound (a CBS catalyst) and a boron hydride compound (step b); and a step of treating a compound [d-1] with a reducing agent (step c). (In the above formulae, Ra and Rb represent the same or different lower alkyl groups; and X1 represents a halogen atom.).Type: GrantFiled: August 24, 2012Date of Patent: November 10, 2015Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Koji Matsuyama, Masanori Hatsuda, Masahiko Yoshinaga, Mitsuhiro Yada, Koichi Tanimoto
-
Patent number: 9056850Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.Type: GrantFiled: October 14, 2009Date of Patent: June 16, 2015Assignees: Janssen Pharmaceutica N.V., Mitsubishi Tanabe Pharma CorporationInventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx, Patrick Hubert J. Nieste, Masanori Hatsuda, Masahiko Yoshinaga, Mitsuhiro Yada, Christopher Teleha
-
Publication number: 20150152082Abstract: The present invention provides an industrially advantageous method for producing an optically active naphthalene compound useful as a therapeutic agent for dermatitis or the like. Specifically, the present invention provides a method for producing an optically active naphthalene compound [I], which comprises: a step of reacting a compound [a-1] and a compound [b-1] with each other in the presence of a base and a catalyst that is composed of a Pd compound and a tertiary phosphine ligand (step a); a step of asymmetrically hydrogenating a compound [c-1] in the presence of a hydrogen donor and a complex that is prepared from a ruthenium compound and a chiral ligand, or alternatively in the presence of an optically active oxazaborolidine compound (a CBS catalyst) and a boron hydride compound (step b); and a step of treating a compound [d-1] with a reducing agent (step c). (In the above formulae, Ra and Rb represent the same or different lower alkyl groups; and X1 represents a halogen atom.Type: ApplicationFiled: August 24, 2012Publication date: June 4, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Koji Matsuyama, Masanori Hatsuda, Masahiko Yoshinaga, Mitsuhiro Yada, Koichi Tanimoto
-
Patent number: 7799929Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): 1 wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): 2 wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: GrantFiled: January 7, 2008Date of Patent: September 21, 2010Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda
-
Publication number: 20100099883Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.Type: ApplicationFiled: October 14, 2009Publication date: April 22, 2010Inventors: Walter Ferdinand Maria Fillers, Rudy Laurent Maria Broeckx, Patrick Hubert J. Nieste, Masanori Hatsuda, Masahiko Yoshinaga, Mitsuhiro Yada
-
Publication number: 20090023918Abstract: The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: —N? or —CH?; R1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of activated blood coagulation factor X.Type: ApplicationFiled: September 5, 2008Publication date: January 22, 2009Inventors: Masahiko SEKI, Shin-ichi YOSHIDA, Nobuhiro YAGI, Masanori HATSUDA, Mayumi KIMURA, Kazuhiko KONDO
-
Patent number: 7439368Abstract: The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: —N? or —CH?; R1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of activated blood coagulation factor X.Type: GrantFiled: June 29, 2004Date of Patent: October 21, 2008Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Masahiko Seki, Shin-ichi Yoshida, Nobuhiro Yagi, Masanori Hatsuda, Mayumi Kimura, Kazuhiko Kondo
-
Publication number: 20080119655Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): 1 wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): 2 wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: ApplicationFiled: January 7, 2008Publication date: May 22, 2008Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda
-
Patent number: 7335778Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: GrantFiled: December 4, 2002Date of Patent: February 26, 2008Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda
-
Publication number: 20060173188Abstract: The present invention provides a process of preparing a compound of the formula [I]: wherein X is a group of the formula: —N? or —CH?; R1 is a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a cyano group or an amino group optionally substituted by a lower alkyl group; Ring A is a nitrogen-containing heterocyclic group; Ring B is an optionally substituted benzene ring or an optionally substituted pyridine ring; and R3 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof, which is useful as an inhibitor of activated blood coagulation factor X.Type: ApplicationFiled: June 29, 2004Publication date: August 3, 2006Inventors: Masahiko Seki, Shin-chi Yoshida, Nobuhiro Yagi, Masanori Hatsuda
-
Publication number: 20050038260Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: ApplicationFiled: December 4, 2002Publication date: February 17, 2005Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda